Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Endocrine 1

Conditions

Pituitary Neoplasms 6Acromegaly 5Neuroendocrine Tumors 3Carcinoid Tumor 3Prostatic Neoplasms 2Pituitary ACTH Hypersecretion 2Growth Disorders 2Gigantism 2Gastro-enteropancreatic neuroendocrine tumor 2Serotonin Syndrome 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Nelson Syndrome 1Melanoma 1Lymphoma, Follicular 1Dumping Syndrome 1Carcinoma, Neuroendocrine 1Adrenocortical Hyperfunction 1ACTH Syndrome, Ectopic 1

Interventions

dactolisib 2Everolimus 2surufatinib 1spartalizumab 1pasireotide 1ganitumab 1fosbretabulin 1cixutumumab 1TH 302 1PM 00104 1ONC206 1Fentanyl 1CLR1404 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neuroectodermal Tumors, Primitive × pasireotide × Clear all
NCT00958841 2016-07-26

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Novartis

Phase 2 Terminated
118 enrolled 11 charts
EndocrineGastrointestinal

ACTH Syndrome, Ectopic, Nelson Syndrome, Pancreatic Neoplasms, Pituitary Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡